DIA, the premier organization dedicated to knowledge exchange that fosters innovation to raise the level of health and well-being worldwide, has appointed Dr Ling Su as President of the DIA Board of Directors.

Dr Su is Senior Vice President and Head of Development Greater China Region of Beijing Novartis Pharma Co. Ltd. He is also an adjunct professor in the School of Pharmacy at Fudan University in Shanghai. Dr Su brings more than 20 years of experience to DIA, specifically in the areas of regulatory affairs, clinical research and development, R&D strategies, pharmacovigilance, pharmacoepidemiology, and outcomes research.

“Through my years of service in the industry, as an active DIA volunteer for 20 years, and now as DIA Board President, I plan on sharing my insight to help DIA and the industry overcome the challenges that we collectively face,” said Dr Su.

Dr Su has served as chair of the DIA Provisional Advisory Council of China and received the DIA Outstanding Service Award in 2000.

Additional DIA Board members include: Minnie Baylor-Henry, JD, RPh President- Elect, Yves Juillet, MD, Immediate Past President, John A Roberts, MBA, Treasurer, Gesine Bejeuhr, Dr Steve Caffe, Dr Nancy A Dreyer, Dr Sergio Guerrero, Dr Truus Janse-de Hoog, Dr Tatsuo Kurokawa, Michele C Livesey, Dr Sandra A Milligan, Frances J Richmond, Jennifer L Riggins, Larisa Nagra Singh, Per Spindler, Dr Beat E Widler, Dr Ning Xu and Dr Sandra L Kweder.

DIA has around 18,000 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices and related medical products. Through its international educational offerings and networking opportunities, it  provides a global forum for knowledge exchange. Headquartered in Horsham, PA, USA, its offices are located at Basel, Switzerland; Tokyo, Japan; Mumbai, India; and Beijing, China.